Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Table 1

Baseline demographic and clinical characteristics (n = 103).

Variable	Pretreatment mean ± SD, range
Age	54.48 ± 4.81, 27.0–71.0
Sex
Male	56 (54.4)
Female	47 (45.6)
Hypertension	34 (33.0)
DM	31 (30.01)
FBG	103.72 ± 43.32, 71.0–299.0
HbA1c (n = 27)	7.62 ± 0.66, 6.60–8.10
AFP	13.87 ± 38.57, 0.70–276.0
HBs-Ag
Positive	0 (0.0)
Negative	103 (100.0)
Prothrombin activity	80.66 ± 10.54, 55.0–100.0
Serum albumin	3.79 ± 0.47, 3.0–4.80
Viral load	414722.16 ± 766382.13, 654.0–4002092.0
End of treatment response	100 (100.0)
Sustained viral response
Positive	3 (3.0)
Negative	97 (97.0)
Ribavirin modification
Positive	8 (8.0)
Negative	92 (92.0)
Previous treatment
Sof + DAC	58 (58.0)
SOF + DAC + RIB	42 (42.0)